Categories
Resources
Your Recalls
Loading...
Get email alerts when new recalls match your interests.
Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide
Failed Impurities/Degradation Specifications
Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Presence of Foreign Tablets/Capsules
Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID.
Marketed without an Approved NDA/ANDA: FDA analysis found the products to be tainted with undeclared Furosemide, Dexamethasone and Chlorpheniramine
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Due to the presence of Toxic yellow oleander
CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
Crystallization
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.